newsfilter
← Latest News
GlobeNewswire·

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027

VRCA
  • Verrica Pharmaceuticals completed enrollment in the first pivotal Phase 3 trial (COVE-2) for YCANTH to treat common warts after a per-protocol interim analysis confirmed no additional patients are needed.
  • The second pivotal trial (COVE-3) has exceeded 50% of its target enrollment ahead of schedule with topline data expected in mid-2027.
  • Topline data for COVE-2 is anticipated in the first quarter of 2027.
  • The COVE-2 study enrolled patients in the U.S. only, while COVE-3 is enrolling patients in the U.S. & Japan.
  • Verrica & Torii Pharmaceutical split Phase 3 program costs 50/50, with Torii funding the first $40 million representing approximately 90% of the current budget.
  • Common warts affect approximately 22 million patients in the U.S. with no existing FDA-approved prescription drug therapies.
  • If successful, YCANTH could become the first FDA-approved prescription treatment for common warts.
  • Verrica intends to seek marketing approval in the U.S. & Japan based on results from the global Phase 3 program.
  • YCANTH is currently the only FDA-approved professional-administered treatment for molluscum contagiosum in patients aged 2+ years.
  • The Phase 3 program includes supportive long-term follow-up (COVE-4) & pharmacokinetics (COVE-5) studies.